Introduction
============

The Schizophrenia Working Group of the Psychiatric Genomics Consortium (PGC) has identified several significant genome-wide associations between genes involved in glutamatergic neurotransmission and schizophrenia.^[@bib1]^ Among these associations, the metabotropic glutamate receptor 3 (*GRM3*) contained the second most significant single-nucleotide polymorphism (SNP) (rs12704290, *P*=3.33 × 10^−10^).^[@bib1]^ This PGC finding complements a number of previous associations between *GRM3* and schizophrenia-related phenotypes, such as prefrontal activation during cognitive tasks,^[@bib2]^ white matter integrity,^[@bib3]^ hippocampal volume in severe obstetric complications,^[@bib4]^ poor cognitive performance (that is, verbal fluency, digit symbol test, perseverative error processing and spatial working memory),^[@bib5],\ [@bib6],\ [@bib7],\ [@bib8],\ [@bib9]^ antipsychotic response in first-episode schizophrenia^[@bib10]^ and positive symptoms severity in treatment-resistant schizophrenia.^[@bib5]^ However, two meta-analyses of *GRM3* SNPs have failed to support an association with schizophrenia risk.^[@bib11],\ [@bib12]^

In the first meta-analysis, Albalushi *et al.*,^[@bib11]^ studied two *GRM3* SNPs (rs1468412 and rs2299225) and more recently Yang *et al.*,^[@bib12]^ examined five *GRM3* SNPs (rs1468412, rs274622, rs917071, rs2299225 and rs6465084). Importantly, in both these meta-analyses, the included studies primarily comprised individuals from Asian populations. This is in contrast to the PGC genome-wide association study (GWAS) that predominately included individuals of European descent, suggesting that the association between *GRM3* and schizophrenia may be population specific. Furthermore, neither of the previous meta-analyses included family-based genetic association studies, which may have biased their results.

Since the publication of the most recent *GRM3* meta-analysis,^[@bib12]^ there have been three additional studies published involving 6027 (2381 schizophrenia and 3646 control) individuals,^[@bib2],\ [@bib6],\ [@bib13]^ indicating a reappraisal is warranted. Thus, the aim of this study was to provide an updated and more comprehensive meta-analysis of the association between *GRM3* genetic variation and schizophrenia by including both case--control and family studies as well as an exploration of potential population stratification.

Materials and methods
=====================

Search strategy
---------------

A systematic search of three electronic databases: PubMed, PsycINFO and Medline (Ovid) was performed using combinations of the following keywords: 'metabotropic glutamate receptor 3', 'GRM 3', 'mGluR3' and 'schizophrenia'. The search was limited to human studies published between January 2002 and December 2016. Two reviewers (SMS and MSM) independently screened the abstracts of all articles identified by the search strategy and then assessed the full-text copies of the eligible articles and extracted the data. In cases where genotype data were unavailable or incomplete, we contacted the corresponding authors and requested the data. A manual search of article bibliographies was completed to identify any non-indexed articles. The SZGene database ([www.szgene.org](http://www.szgene.org)) was also used as a resource for genotype data collection. The 'preferred reporting items for systematic review and meta-analysis protocols' (PRISMA-P)^[@bib14]^ was followed in the reporting of this meta-analysis.

Inclusion criteria and data extraction
--------------------------------------

The following inclusion criteria were used for study selection: (1) examination of *GRM3* polymorphisms in schizophrenia, (2) case--control or family-based genetic association study, (3) schizophrenia diagnosis using a standard classification system (for example, DSM-IV, ICD 10 and so on)^[@bib15]^ and (4) provided sufficient genotype or allelic data for calculation of an odds ratio (OR).

From the included studies, the following data were extracted: (a) author(s) and publication year, (b) number of cases and controls or family sample size, (c) country of origin or ethnicity of study participants, (d) diagnostic criteria used, (e) SNP reference sequence number or marker identifier, (f) the publication identification number (for example, PubMed ID) and (g) genotype counts and/or allele counts in cases and controls or family samples (transmission/non-transmission from heterozygous parents to affected offsprings). The extracted data are provided in [Supplementary File 1](#sup1){ref-type="supplementary-material"}. We also extracted haplotype data when available, but these data were not analyzed because there were no two haplotypes that appeared in three or more selected studies.

Statistical analysis
--------------------

Data were analyzed using *R* version 3.3.0 (R Foundation for Statistical Computing, Vienna, Austria). The *meta*^[@bib16]^ and *metafor*^[@bib17]^ packages were used to conduct the meta-analyses. The OR with 95% confidence intervals (CIs) was used as the effect size estimator assuming an additive genetic model.

The method proposed by Kazeem and Farrall^[@bib18]^ was used to calculate the effect size for transmission disequilibrium test studies, where the ORs were estimated from the number of transmissions versus non-transmissions of the minor or high-risk allele to schizophrenia cases from heterozygous parents. For case--control studies, ORs were calculated by contrasting the ratio of counts of the minor versus major allele or, when known, high-risk versus low-risk allele in schizophrenia cases versus healthy controls. Two-tailed *P*-values were reported and were indicated accordingly in the text.

All statistical tests (except for the *Q*-statistic) were considered statistically significant at *P*\<0.05. Due to differences in study design and sample characteristics, considerable heterogeneity was expected between the studies. Therefore, the pooled ORs were calculated using the random-effects models with the DerSimionian--Laird (DL) estimator,^[@bib19]^ which is based on a normal distribution. The standard error estimates were adjusted using the Hartung--Knapp--Sidik--Jonkman^[@bib20],\ [@bib21]^ correction, which then calculates the corresponding 95% CIs based on the *t*-distribution. The Hartung--Knapp--Sidik--Jonkman method generally outperforms the DL approach on type-I error rates when there is heterogeneity, and the number of studies in the meta-analysis is small.^[@bib22],\ [@bib23]^

The presence of outliers or influential studies may distort the robustness of the conclusions from the meta-analysis, and as such it is recommended that analysis of potential outlier and influential studies should be an integral part of meta-analysis.^[@bib24],\ [@bib25]^ Outliers and influential studies were identified according to the recommendations of Viechtbauer and Cheung.^[@bib26]^ Studies with observed effects that are well separated from the rest of the data are considered outliers. Such studies were identified using studentized deleted residuals, with absolute values \>1.96 indicative of outliers. An influential study leads to considerable changes to the fitted model and a range of case-deletion diagnostics adapted from linear regression can be used to identify these studies, including the DFFITS, DFBETAS and COVRATIO statistics (see Viechtbauer and Cheung^[@bib26]^ for more information). Potential outliers and influential studies were omitted, and the analyses were then re-run to determine their influence on the pooled effect size. Removal of these studies would substantially reduce the amount of heterogeneity and increase the precision of the pooled effect size, that is, narrowing the confidence interval.

Heterogeneity in effect sizes across studies was tested using the *Q*-statistic (with *P*\<0.10 indicating significant heterogeneity) and its magnitude was quantified using the *I*^2^ statistic, which is an index that describes the proportion of total variation in study effect size estimates that is due to heterogeneity and is independent of the number of studies included in the meta-analysis and the metric of effect sizes.^[@bib27]^ As the *Q*-statistic has low power when the number of studies is small,^[@bib28]^ 95% prediction intervals were calculated to quantify the extent of heterogeneity in the distribution of effect sizes.^[@bib29]^ The prediction interval is an estimation of the range within which 95% of the true effect sizes are expected to fall.

Moderator analyses for study design (case--control versus transmission disequilibrium test) and ancestry (East Asian versus European) were conducted using mixed-effects meta-analyses. For this method, studies within potential moderator groups were pooled with the random-effects model, while tests for significant differences between the groups were conducted with the fixed-effects model. The Hartung--Knapp--Sidik--Jonkman adjustment was used if there were at least three studies in each group; otherwise, the unadjusted DL method was used.

Publication bias was evaluated by funnel plots and the trim-and-filled procedure,^[@bib30]^ which yields an estimate of the effect size after publication bias has been taken into account.^[@bib31]^ A test for funnel plot asymmetry was only performed if the number of studies was 10 or greater.^[@bib32]^ The test proposed by Harbord *et al.*^[@bib33]^ was used to quantify the bias captured by the funnel plot and tested whether it was statistically significant.

Results
=======

A total of 20 (17 case--control, 3 family-based) studies representing 11 318 schizophrenia cases, 13 820 controls and 486 parent--proband trios were eligible for further analysis ([Supplementary Figure S1](#sup1){ref-type="supplementary-material"} and [Table 1](#tbl1){ref-type="table"}). Among the 48 *GRM3* SNPs examined in these studies, 14 SNPs were assessed in three or more studies and were subjected to meta-analysis ([Figure 1](#fig1){ref-type="fig"}). Significant associations were not found for any of the 14 SNPs when examining all available studies ([Supplementary Table S1](#sup1){ref-type="supplementary-material"}). However, after removal of an outlier study^[@bib34]^ the rs2237562 C allele was associated with greater schizophrenia risk (*k*=4, OR=1.06, 95% CI=1.02--1.11, *P*=0.017) ([Figure 2a](#fig2){ref-type="fig"}). In contrast, removal of influential studies^[@bib35],\ [@bib36]^ showed the C alleles for both rs13242038 (*k*=3, OR=0.90, 95% CI=0.85--0.96, *P*=0.016) and rs917071 (*k*=8, OR=0.94, 95% CI=0.91--0.97, *P*=0.003) to be associated with lower risk of the disorder ([Figures 2b and c](#fig2){ref-type="fig"}).

Low to moderate heterogeneity (I^2^=0.0--34.6%) was present across the studies examining these three significant SNPs, although removal of outlier/influential studies reduced heterogeneity to 0% for all three SNPs ([Supplementary Table S1](#sup1){ref-type="supplementary-material"}). No evidence of moderation by study design or ancestry was detected ([Supplementary Table S2 and S3](#sup1){ref-type="supplementary-material"}).

Publication bias was evaluated for rs6465084 and rs1468412 as these were the only two SNPs with ten or more studies. The regression test for funnel plot asymmetry was statistically significant for studies examining rs1468412 (*t*\[10\]=2.35, *P*=0.040) ([Supplementary Figure S2](#sup1){ref-type="supplementary-material"}). After adjustment for publication bias with the trim-and-fill procedure, the odds ratio was decreased to 0.96 (95% CI=0.86, 1.07, *P*=0.426; the number of filled studies was 2. Given that there was a subtle reduction in the pooled odds ratio, the impact of publication bias was likely modest. For rs6465084 the regression test for funnel plot asymmetry was not statistically significant (*t*\[8\]=0.58, *P*=0.578) ([Supplementary Figure S3](#sup1){ref-type="supplementary-material"}).

Discussion
==========

We found three SNPs (rs2237562, rs13242038, rs917071) in *GRM3* that were significantly associated with schizophrenia. Our results differ from the two previous meta-analyses^[@bib35],\ [@bib36]^ that did not detect an association between *GRM3* genetic variation and schizophrenia. However, our positive results were only apparent after removal of outlier or influential studies, a method recommended^[@bib24],\ [@bib25]^ but not employed in the previous two meta-analyses.^[@bib11],\ [@bib12]^

Importantly, our meta-analysis supports finding from the PGC GWAS, which identified *GRM3* as one of 108 loci associated with schizophrenia.^[@bib1]^ In fact, the top PGC GWAS SNP in *GRM3* (rs12704290, *P*=1.0 × 10^−10^) is in moderate to strong linkage disequilibrium (LD) with two (rs2237562: *D*′=1.00, *r*^2^=0.485; rs917071: *D*′=0.64, *r*^2^=0.199) of the three significant SNPs we detected in the current meta-analysis. The association between rs2237562 and schizophrenia is particularly interesting for two reasons. First, among the 14 SNPs eligible for meta-analysis, the rs2237562 SNP had the strongest LD with the top *GRM3* GWAS hit (rs12704290), which has only been examined in one case--control study^[@bib6]^ to date. Second, in the PGC GWAS the T allele of rs2237562 was associated with schizophrenia risk (OR=1.04, *P*=8.3 × 10^−5^) while in our meta-analysis the C allele was associated with risk. One potential explanation for this discrepancy is population stratification. The PGC GWAS was predominately focused on people of European descent with people of Asian descent represented in only 3.5% (Japanese: 0.6%, Singapore: 1.2% and Chinese: 1.7%) of the studied population. Conversely, the four studies contributing to our significant meta-analysis finding were exclusively conducted in the East Asian population.^[@bib6],\ [@bib36],\ [@bib39],\ [@bib45]^ Notably, the two alleles for rs2237562 (T/C) occurred within similar haplotype blocks and at comparable frequencies in the European and in East Asian population ([Supplementary Figures S4 and S5](#sup1){ref-type="supplementary-material"}).

In fact, inclusion of the one outlier study,^[@bib34]^ which was conducted in a German population and concurred with the PGC findings, eliminated the pooled effect detected among the more ancestral homogenous East Asian studies. Thus, the 'risk' allele for rs2237562 may be ancestry dependent, with potential implications for calculating polygenic risk scores that include this SNP within non-European populations.

It is also noteworthy that current evidence supporting an association between *GRM3* genetic variation and schizophrenia susceptibility as well as cognitive and neuroimaging indices have been centered on SNPs in exon 3 and its adjacent introns.^[@bib46]^ However, among the five SNPs we examined in this region, only the intronic rs2237562 SNP (discussed above) was supported. Yet, upstream of this region in the intron between exons I and II, we showed the C alleles for two SNPs (rs13242038 and rs917071) were associated with schizophrenia risk. Conversely, the alternative (T) allele for both SNPs was associated with lower schizophrenia risk (rs13242038: OR=0.95, *P*=2.7 × 10^−4^; rs917071: OR=0.95, *P*=0.056) in the PGC GWAS, suggesting again a potential population stratification effect. However, the studies contributing to the meta-analyses of these two SNPs were not ancestrally homogenous (rs13242038: 68% East Asian and 32% Caucasian; rs917071: 49% East Asian and 51% Caucasian) and moderation analysis did not detect an ancestry effect. Furthermore, the removed influential studies by Norton *et al.*^[@bib35]^ for rs13242038 and Tochigi *et al.*^[@bib36]^ for rs917071 were conducted in Caucasian and Asian populations, respectively. Thus, the discordance between our meta-analytical findings and those of the PGC is likely not a result of population structure. Previous research supports the PGC findings, in part, in that individuals with schizophrenia who had the rs13242038 T allele and a history of severe obstetric complications (OCs) had larger hippocampi. However, similar support for rs917071 is absent in that previous neuroimaging^[@bib4]^ and cognitive^[@bib6],\ [@bib7]^ studies in schizophrenia have been negative to date.

The mechanisms underpinning the genetic associations between the three *GRM3* SNPs and schizophrenia are still unknown. Gene expression, more specifically gene splicing, is postulated to mediate the pathophysiological effects of allelic variation.^[@bib46],\ [@bib47]^ Four alternative splice variants have been reported in the human brain: full-length *GRM3* (2.8 kb), *GRM3* with exon 2 deleted (GRM2Δ3, 2.2 kb), *GRM3* with exon 4 deleted (GRM3Δ4, 1.8 kb) and *GRM3* with exons 2 and 3 deleted (GRM3Δ2Δ3, 1.4 kb).^[@bib48],\ [@bib49]^ A previous study^[@bib50]^ found that an exon 3 SNP (rs2228595) predicted increased transcript expression of the GRM3Δ4 splice variant that encodes a truncated receptor in the dorsolateral prefrontal cortex of schizophrenia patients, suggesting *GRM3* SNPs that are in LD with rs2228595 may also affect *GRM3* splicing. Interestingly, the rs2228595 is in strong LD with the PGC GWAS SNP (rs12704290: *D*′=1.0, *r*^2^=0.011) and our meta-analysis significant SNPs (rs2237562: *D*′=1.0, *r*^2^=0.170; rs917071: *D*′=0.757, *r*^2^=0.098), but we found no association of rs2228595 with schizophrenia in the current meta-analysis (*k*=5, OR=1.06, 95% CI=0.73--1.54, *P*=0.706). Nevertheless, there is a preliminary indication that *GRM3* genetic variation may influence gene splicing, but additional research interrogating how this splicing may contribute to the pathophysiology of schizophrenia is warranted.

In conclusion, we have identified novel meta-analytically derived associations between polymorphisms within the fourth (rs2237562) and second (rs13242038, rs917071) introns of *GRM3* with schizophrenia. Two of these SNPs (rs2237562, rs917071) were in strong-to-moderate LD with the top PGC SNP identified in the largest schizophrenia GWAS to date.^[@bib1]^ We further showed that the rs2237562 allele associated with 'risk' for schizophrenia is likely ancestry dependant. As such, our results support the GWAS-implicated link between *GRM3* genetic variation and schizophrenia risk as well as support the notion that alleles conferring this risk may be population specific. These findings provide further justification for the future study of the mechanism(s) by which *GRM3* genetic variation contributes to schizophrenia risk.
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![Schematic diagram of the *GRM3* structure with locations of SNPs is examined in this meta-analysis. Single-nucleotide polymorphisms (SNPs) significantly associated with schizophrenia in this meta-analysis are underlined. \*This SNP was excluded in this meta-analysis due to fewer than three studies but was the most significant *GRM3* SNP in the PGC GWAS.^[@bib1]^](tp2017172f1){#fig1}

![Forest plots of (**a**) rs2237562, (**b**) rs13242038 and (**c**) rs917071 association with schizophrenia before and after excluding outlier/influential studies. CI, confidence interval; OR, odds ratio; RE model, random-effect model.](tp2017172f2){#fig2}

###### Descriptive characteristics of selected studies in meta-analysis

  *Author*                                                *Year*  *Case/control*   *Ancestry*      *Method*        *Criteria*
  ------------------------------------------------------ -------- ---------------- --------------- --------------- ------------
  Marti *et al.*^[@bib37]^,[a](#t1-fn1){ref-type="fn"}     2002   265/227          German          Case--control   DSM-III-R
  Marti*et al.*^[@bib37]^,[a](#t1-fn1){ref-type="fn"}      2002   288/162          German          Case--control   DSM-III-R
  Marti*et al.*^[@bib37]^,[a](#t1-fn1){ref-type="fn"}      2002   128              German          Family study    DSM-III-R
  Fujii*et al.*^[@bib38]^                                  2003   100/100          Japanese        Case--control   DSM-IV
  Chen *et al.*^[@bib39]^                                  2005   752/752          Chinese         Case--control   DSM-IV
  Norton *et al.*^[@bib35]^                                2005   674/716          Caucasian, UK   Case--control   DSM-IV
  Tochigi *et al.*^[@bib36]^                               2006   402/468          Japanese        Case--control   DSM-IV
  Bishop *et al.*^[@bib40]^                                2007   207/147          Caucasian, US   Case--control   CASH
  Schwab *et al.*^[@bib34]^                                2008   242              German          Family study    DSM-III
  Mössner *et al.*^[@bib9]^                                2008   631/519          German          Case--control   ICD-10
  Albalushi *et al.*^[@bib11]^                             2008   1916/1915        Japanese        Case--control   DSM-IV
  Nunokawa *et al.*^[@bib41]^                              2008   2358/2433        Japanese        Case--control   DSM-IV
  Nicodemus *et al.*^[@bib42]^                             2008   116              Caucasian       Family study    DSM-IV
  Betcheva *et al.*^[@bib43]^                              2009   255/556          Bulgarian       Case--control   DSM-IV
  Jönsson *et al.*^[@bib44]^                               2009   582/1473         Scandinavian    Case--control   DSM-IV
  Jia *et al.*^[@bib45]^                                   2014   433/619          Chinese         Case--control   DSM-IV
  Mounce *et al.*^[@bib3]^                                 2014   74/87            Caucasian, US   Case--control   DSM-IV
  O\'Brien *et al.*^[@bib13]^                              2014   1235/1309        Caucasian, UK   Case--control   DSM-IV
  Chang *et al.*^[@bib6]^                                  2015   1115/2289        Chinese         Case--control   DSM-IV
  Kinoshita *et al.*^[@bib2]^                              2015   31/48            Japanese        Case--control   DSM-IV

These three studies were published in the same article.^[@bib37]^
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